TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03394911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 250mg healthy adult male facial skin surface lipid liquid pheromone
Description: Human Pheromone provided p.o. to tox-screen verified opioid drug addict

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 250mg healthy adult male facial skin surface lipid liquid pheromone
Description: Human Pheromone provided p.o. to tox-screen verified opioid drug addict
Study: NCT03392493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted hand rehabilitation
Description: Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted hand rehabilitation
Description: Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
Study: NCT04882423

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: grilled hamburger (7 oz) with no vegetables
Description: Test meal 1: grilled hamburger (7 oz) with no vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)
Description: Test meal 2: grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)
Description: Test meal 3: grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
Description: Test meal 4: grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).
Study: NCT03557528

Intervention type: PROCEDURE
Intervention: Laparoscopic colorectal resection
Description: Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes

Intervention type: PROCEDURE
Intervention: Laparoscopic colorectal resection
Description: Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
Study: NCT00003138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion
Description: Red cell and platelet transfusions
Study: NCT03049995

Intervention type: PROCEDURE
Intervention: Diastolic function SE
Description: SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).

Intervention type: PROCEDURE
Intervention: Mitral regurgitation SE
Description: SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).

Intervention type: PROCEDURE
Intervention: Pulmonary hemodynamics SE
Description: SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.

Intervention type: PROCEDURE
Intervention: Pulmonary hemodynamics SE
Description: SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.

Intervention type: PROCEDURE
Intervention: Pulmonary hemodynamics SE
Description: SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.

Intervention type: PROCEDURE
Intervention: Coronary flow reserve SE
Description: SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
Study: NCT02779881

Intervention type: DIETARY_SUPPLEMENT
Intervention: Extensively hydrolyzed casein formula plus LGG
Study: NCT01188538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epiduo gel
Description: Once daily application on the face in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPO
Description: Once daily application on the face in the evening for 12 weeks
Study: NCT00622401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell/Tumor Fusion Vaccine
Description: Vaccine is derived from the participants dendritic cells and tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell/Tumor Fusion Vaccine
Description: Vaccine is derived from the participants dendritic cells and tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell/Tumor Fusion Vaccine
Description: Vaccine is derived from the participants dendritic cells and tumor cells
Study: NCT00742521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucose clamp
Description: Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glucose clamp
Description: Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
Study: NCT02770027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Crystalloid
Description: Crystalloid is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous HES
Description: HES is administered to maintain stroke volume variation \< 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
Study: NCT02918669

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point.
Study: NCT03842046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine infusion
Description: In parturients allocated to the phenylephrine group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine infusion
Description: In parturients allocated to the norepinephrine group group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
Study: NCT01023217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir 1 mg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Entecavir 1 mg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine (Zeffix) 100 mg/day orally
Study: NCT04092777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strong Minds
Description: The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
Study: NCT03056833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
Study: NCT04065698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV521
Description: Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
Study: NCT00622401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-12
Description: Given subcutaneously at dose of 30ng/kg
Study: NCT04590599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: IBI310 3 mg/kg,Q3W, for a total of 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo Q3W, for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg,Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab 200mg,Q3W
Study: NCT01118780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered by mouth, daily for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by mouth, daily for 10 weeks
Study: NCT03186092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory muscle training
Description: The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham muscle training
Description: sham comparator
Study: NCT00740324

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-11
Description: 20 mg butylscopolammonium bromide after administration of NPO-11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-11
Description: NPO-11 after administration of NPO-11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-11
Description: 1 mg glucagons after administration of NPO-11
Study: NCT04828356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology application is an energy balancing system with its own pressure technique that provides recovery by rubbing the reflex (nerve endings) points, stroking and applying pressure during squeezing movements. Thanks to the pressure and massage applied to the reflex points, the energy blockages are broken and this energy flow is distributed in a balanced way to the relevant organs.
Study: NCT02806947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m\^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
Study: NCT00856258

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF 03882845 and Placebo
Description: The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF 03882845 and Placebo
Description: The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF 03882845 and Placebo
Description: The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF 03882845 and Placebo
Description: The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
Study: NCT00032617

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: trauma-focused exposure therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: therapy that focuses on current problems
Study: NCT03350841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma PRP
Description: blood sample is collected to prepare platelet rich plasma injected in the canal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root canal treatment
Description: conventional root canal treatment and obturation with guttapercha
Study: NCT02287870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Description: 60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
Study: NCT01080456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 1 mg capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 1 mg capsule
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT00888069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: Single dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: Single dose oral administration
Study: NCT00888069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Injection
Description: single IV injection
Study: NCT04555174

Intervention type: DEVICE
Intervention: Orsiro Mission DES
Description: Percutaneous Coronary Intervention (PCI)
Study: NCT02490397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day Light
Description: Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Room Light
Description: Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
Study: NCT01529814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant with new abutment connection
Description: New abutment connection implant system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nanotite Certain Tapered implant
Description: Nanotite Certain Tapered (standard abutment connection) implant
Study: NCT03049007

Intervention type: DIAGNOSTIC_TEST
Intervention: Survey
Description: Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).

Intervention type: DIAGNOSTIC_TEST
Intervention: Survey
Description: Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
Study: NCT02539303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yamani-15/5 chemical solution
Description: A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
Study: NCT03670498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2 channel Electrical Stimulation Device
Description: electrical stimulation at muscles which related with deglutition
Study: NCT02198989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer support and yoga music therapy
Description: Patients in the intervention group will receive peer support and yoga music therapy before bed.
Study: NCT02995213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerometer based feedback about paretic arm use
Study: NCT01847898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebral Body Stenting (VBS)
Description: Vertebral Augmentation with a Stent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty
Description: Vertebral Augmentation with a Balloon (device not specified)
Study: NCT04354441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine sulfate 200 MG
Description: Hydroxychloroquine sulfate (Plaquenil) 2MG will be taken twice a day for 10 days. Participants will be couriered the medication upon giving consent and will start taking the medication immediately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo that is identical in appearance to the study medication will be taken twice a day for 10 days. It will be couriered to participants upon giving consent. They will start taking the medication immediately.
Study: NCT03286296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection
Description: LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
Study: NCT02264171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin HCl
Study: NCT00622401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-12
Description: Given subcutaneously at dose of 100ng/kg
Study: NCT02264171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Study: NCT01978509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low volume prep (Prepopik)
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate volume prep (Moviprep)
Description: Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.